Dabigatran etexilate is a precursor drug of dabigatran that is enzymatically hydrolyzed in vivo to the coagulant-active dabigatran, which exerts its anticoagulant effect through direct inhibition of thrombin. Dabigatran etexilate mesylate capsules, originally developed by Boehringer Ingelheim under the trade name of Pradaxa^®, were approved for marketing by EMA in March 2008 and then approved by FDA in 2010. After the launch, its sales value peaked at USD1.60 billion in 2013. The sales value then started to decrease due to the launch of other competitive anticoagulants like rivaroxaban and apixaban.

In March 2013, Dabigatran etexilate capsules were approved in China for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation, under the trade name of Taibiquan^® with the specifications of 110 mg/capsule and 150 mg/capsule. In 2017, Dabigatran etexilate immediate-release formulation for oral use has been included in the Category B drugs in the latest China National Reimbursement Drug List. In March 2020, Chia Tai Tianqing’s generic dabigatran etexilate capsules were approved by the NMPA for marketing in China, followed by Jiangsu Hansoh Pharmaceutical and Chengdu Easton Bio Pharmaceuticals in early 2021. And It is expected that, from 2021 to 2025, more generic dabigatran etexilate drugs will be approved.

According to CRI’s market research, the sales value of dabigatran etexilate in China declined to approximately CNY329 million (USD50.6 million) in 2020 due to COVID-19. And China’s dabigatran etexilate market was entirely dominated by Boehringer Ingelheim International GmbH before 2020. Despite the launch of Chia Tai Tianqing’s dabigatran etexilate in 2020, Boehringer Ingelheim International GmbH still held more than 99% share of the dabigatran etexilate market in China in terms of sales value. It is expected that Boehringer Ingelheim International GmbH’s share of China’s dabigatran etexilate market will decline for more generic products will become available.

Topics Covered:

• Impact of COVID-19 on China’s Dabigatran Etexilate Market
• Development Environment of Dabigatran Etexilate in China
• Sales Volume of Dabigatran Etexilate in China
• Sales Volume and Value of Dabigatran Etexilate in China by Region
• Major Dabigatran Etexilate Manufacturers in China and Their Market Shares
• Sales Price of Dabigatran Etexilate in China
• Prospects of China’s Dabigatran Etexilate Market, 2021-2025

The post Research Report on China’s Dabigatran Etexilate Market, 2021-2025 first appeared on CRI Report.

More than 300 million people worldwide are affected by osteoporosis. With the advent of an aging world, many middle-aged and older adults have varying degrees of osteoporosis. The incidence is about 40% in postmenopausal women and about 15% in men. Due to the increasingly aging population, osteoporosis and osteoporotic fractures have become major risk factors threatening public health in China. According to a survey released in October 2020, the prevalence of osteoporosis in China was 19.2% in people aged 50 years and older and 32.0% in people aged over 65 years with 10.7% in men and up to 51.6% in women. By the end of 2020, the number of osteoporosis patients in China was over 150 million and it has kept growing.

Global Nucleic Acid Therapeutics CDMO Market to Reach $4,463.7 Million by 2030

The mechanisms of action of osteoporosis medication are divided into three types: inhibition of bone resorption, promotion of bone formation, and dual action of both. The development of clinical application of bisphosphonates in the treatment of osteoporosis began in the 1990s and has undergone three generations of development. The representative drugs of the first generation are etidronate sodium and disodium clodronate; the representative drugs of the second generation are pamidronate sodium and ibandronate sodium; the representative drugs of the third generation are alendronate sodium, risedronate sodium, zoledronic acid and incardronate sodium. At present, these representative drugs have all been marketed in China.

Zoledronic acid was originally developed by Novartis (trade name: ZOMETA^®) and was initially approved for marketing in the United States in 2001 under the trade name of Zometa^® (4mg), mainly for the treatment of excessive calcium in the blood caused by cancer. In 2007, zaoledronic under the trade name of Reclast^® (5mg) was approved by the US and Europe for the treatment of post-menopausal osteoporosis in women. In 2008, Reclast was also indicated for the prevention of hip fractures in women and men. In 2009, Reclast was approved by the FDA for the treatment of osteoporosis and by the EMA of Europe for the treatment of osteoporosis caused by steroid therapy in men and menopausal women.

According to CRI’s market research, 4mg of zoledronic acid injection was marketed by Novartis in China in 2004, while 5mg of zoledronic acid injection for osteoporosis was approved in China in 2009. Subsequently, several companies’ generic zoledronic acid drugs were marketed in China, decreasing Novartis’ share of zoledronic acid market in China.

Global Nucleic Acid Isolation and Purification Market: Focus on Product, End User, Region/Country Data and Competitive Landscape – Analysis and Forecast, 2021-2031

According to CRI’s market research, in 2020, the sales value of zoledronic acid in China declined to approximately CNY 507 million (USD78 million) because of COVID-19, with a CAGR of approximately -3.9% from 2016 to 2020. Since Novartis’ original drug sells at a much higher price than generic drugs, local Chinese company Chia Tai Tianqing Pharmaceutical then ranked the first in terms of sales value and volume in China’s zoledronic acid market in 2020.

CRI expects that from 2021 to 2025, China’s zoledronic acid market will see growth as COVID-19 is effectively controlled in China.

Topics Covered:

• Impact of COVID-19 on China’s Zoledronic Acid Market
• Development Environment of Zoledronic Acid in China
• Sales Volume of Zoledronic Acid in China
• Sales Volume and Value of Zoledronic Acid in China by Region
• Major Zoledronic Acid Manufacturers in China and Their Market Shares
• Sales Price of Zoledronic Acid in China
• Prospects of China’s Zoledronic Acid Market, 2021-2025

The post Research Report on China’s Zoledronic Acid Market, 2021-2025 first appeared on CRI Report.

Lung cancer is the most common type of cancer and the leading cause of cancer deaths. 19.29 million new cancer cases were diagnosed worldwide in 2020, 4.57 million of which were in China, accounting for 23.7%. There were 3 million cancer deaths in China in 2020, of which lung cancer deaths were up to 710,000, accounting for 23.8%.

Lung cancer is divided into small cell lung cancer and non-small cell lung cancer (NSCLC). Of all the lung cancer cases, NSCLC ones account for about 80-85% with most of them being diagnosed as advanced lung cancer (locally advanced or metastatic disease).

First-generation EGFR-TKI (epidermal growth factor receptor tyrosine kinase inhibitor), represented by gefitinib, can significantly prolong the median survival period of patients with advanced lung cancer carrying EGFR-sensitive mutations and improve the quality of life of patients.

Gefitinib, originally developed by AstraZeneca, is the world’s first marketed EGFR-TKI for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer with sensitive mutations in the EGFR gene, as well as patients with locally advanced or metastatic non-small cell lung cancer who have received prior chemotherapy.

AstraZeneca’s gefitinib, with the trade name of Iressa^®, was approved in the United States in 2003 and in China in 2004.

Gefitinib was recommended by the Non-Small Cell Lung Cancer, Version 1.2020, NCCN Clinical Practice Guidelines and the Guidelines of Chinese Society of Clinical Oncology (CSCO) on Treatment of Primary Lung Cancer (2019) as a first-line drug for treatment for patients with EGFR-mutated non-small cell lung cancer, and has been included in the Category B in China’s medical insurance in 2019 and the National Essential Medicines List (2018 edition).

Before the launch of domestic generic drugs in China, the only gefitinib available in the market was the original drug Iressa with a high price. In 2017, the first generic drug from Qilu Pharmaceutical was approved for marketing in China to compete with Iressa, followed by generic drugs from Chia Tai Tianqing Pharmaceutical and Sichuan Kelun Pharmaceutical, Jiangsu Hengrui Medicine and Yangtze River Pharmaceutical.

In September 2019, in the Chinese government’s centralized drug-procurement, the gefitinib drugs of Qilu Pharmaceutical, Chia Tai Tianqing Pharmaceutical and AstraZeneca were selected at prices of CNY257, CNY450 and CNY547, with the specification of 25 mg (a box of 10 tablets). The price of AstraZeneca’s Iressa was reduced by 76%.

According to CRI’s market research, before 2019, the sales value of China’s gefitinib market kept growing year by year. In 2019, the average price of gefitinib decreased significantly due to the Chinese government’s centralized drug-procurement program. Therefore, although the sales volume of gefitinib in China increased in 2019, its sales value declined greatly.

In 2020, both of them decreased due to the COVID-19 outbreak, which impacted the proper function of Chinese healthcare institutions. The sales value of gefitinib in China was approximately CNY312 million (USD48.1 million) in 2020, with a CAGR of about 1.3% from 2016 to 2020.

According to CRI’s market research, although AstraZeneca’s original drug, Iressa, is much more expensive than generic drugs from local Chinese companies, it still held more than 70% share of the market in 2020 in terms of sales value.

CRI expects that from 2021 to 2025, China’s gefitinib market will show a recovery growth in both sales volume and value due to the effective control of COVID-19 and the resumption of proper operation of healthcare facilities.

CRI expects that, from 2021 to 2025, new cases of lung cancer in China will continue to grow as a result of environmental pollution and poor lifestyles. And with the growing income of Chinese residents, they are able to pay more for medical expenses. Therefore, China’s alectinib market is expected to grow in both sales volume and value during this period.

Topics Covered:

• Impact of COVID-19 on China’s Gefitinib Market
• Development Environment of Gefitinib in China
• Sales Volume of Gefitinib in China
• Sales Volume and Value of Gefitinib in China by Region
• Major Gefitinib Manufacturers in China and Their Market Shares
• Sales Price of Gefitinib in China
• Major Gefitinib Producers in China
• Prospects of China’s Gefitinib Market, 2021-2025

Related Reports: Global Bladder Cancer Detection Kit Market Analysis and Forecast Report 2030
Related Reports: Global Neoantigen Cancer Vaccine Market: Focus on Approach, Line of Therapy, Type, Application, Treatment Strategy, and Country-Wise Analysis – Analysis and Forecast, 2024-2031
Related Reports: Global Lung Cancer Surgery Market Analysis and Forecast Report 2030

The post Research Report on China’s Gefitinib Market, 2021-2025 first appeared on CRI Report.

According to CRI’s market research, the sales value of Caspofungin in the Chinese market increased year by year from 2016 to 2019. Due to the impact of COVID-19 on the overall diagnosis and treatment services of Chinese hospitals, the sales value of Caspofungin in the Chinese market decreased to CNY 801 million in 2020 and the CAGR of Caspofungin in sales value from 2016 to 2020 is 15.45%.

CRI expects that with the relief of COVID-19, the sales of Caspofungin in the Chinese market will have a restorative growth from 2021 to 2025. In addition, Caspofungin has the characteristics of broad antifungal spectrum, excellent curative effect and high safety. Based on these advantages, the sales value and sales volume of Caspofungin in the Chinese market still has room to rise. By the first half of 2021, in addition to the original research companies, a total of 5 domestic companies have been approved, including Huadong Medicine Co.,Ltd., Borui Pharmaceutical Technology Development Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Haisco Pharmaceutical Group Co., Ltd. It is expected that with the addition of new manufacturers, the sales value of Caspofungin will continue to rise.

Topics Covered:

• -The impact of COVID-19 on China’s Caspofungin market
• – Sales value of China’s Caspofungin 2016-2020
• – Competitive landscape of China’s Caspofungin market
• – Prices of Caspofungin in China
• – Prices of Caspofungin in China by regions and manufacturers
• – Analysis on factors affecting the development of China’s Caspofungin market
• – Prospect of China’s Caspofungin market from 2021 to 2025

The post Investigation Report on China’s Caspofungin Market 2021-2025 first appeared on CRI Report.

According to CRI’s market research, the sales value of tigecycline in the Chinese market increased year by year at a compound annual growth rate of 43.45% from 2016 to 2019. Due to the impact of COVID-19 on the overall diagnosis and treatment services of Chinese hospitals, the sales value of tigecycline in the Chinese market decreased to CNY 885 million in 2020 and the CAGR of tigecycline sales value from 2016 to 2020 is 28.64%.

CRI expects that the sales value of tigecycline in the Chinese market will have a restorative growth from 2016 to 2020 with the relief of COVID-19. According to the latest set of data disclosed by the World Health Organization, 700,000 people worldwide die each year due to “super bacteria” infection, and 230,000 newborns die prematurely because of this. It can be estimated that by 2050, the number of deaths may exceed 10 million. Therefore, the sales value and sales volume of tigecycline against “super bacteria” such as methicillin-resistant Staphylococcus aureus (MRSA) will continue to rise. By the first half of 2021, the new indication for tigecycline in the Chinese market-community and hospital-acquired pneumonia is under review. It can be expected that with the increase in new indications in the future, the sales value and sales volume of tigecycline have room to rise.

Topics Covered:

• -The impact of COVID-19 on China’s Tigecycline market
• – Sales value of China’s Tigecycline 2016-2020
• – Competitive landscape of China’s Tigecycline market
• – Prices of Tigecycline in China
• – Prices of Tigecycline in China by regions and manufacturers
• – Analysis on factors affecting the development of China’s Tigecycline market
• – Prospect of China’s Tigecycline market from 2021 to 2025

The post Investigation Report on China’s Tigecycline Market 2021-2025 first appeared on CRI Report.

According to CRI’s market research, the sales of Capecitabine in the Chinese market increased year by year from 2016 to 2019. Due to the impact of the COVID-19 pandemic on the hospital’s overall diagnosis and treatment services, sales in 2020 decreased to CNY 914 million, a year-on-year decrease of 9.31%. The CAGR of Capecitabine sales in the Chinese market from 2016 to 2020 is 1.21%.

CRI expects that with the easing of the COVID-19 pandemic, the sales of Capecitabine in the Chinese market will have a restorative growth in 2021-2025. In 2020, the number of COVID-19 breast cancers worldwide reached 2.26 million, and the number of colon cancers reached 1.93 million, both of which were on the rise. The number of breast and colon cancers in China will be also on the rise in the future. Therefore, the sales volume of Capecitabine, which is used to inhibit the anti-tumor activity of a variety of solid tumors, will increase with the increase in the number of breast cancer and colon cancer patients in China. There is also room for sales to rise. In addition, by the end of 2020, a number of companies led by Chengdu Yuandong Biopharmaceuticals have already reported for Capecitabine generic drug approval. In the next few years, more manufacturers will join the Chinese market. The sales volume and sales of Capecitabine in China are expected to rise.

Topics Covered:

• -The impact of COVID-19 on China’s Capecitabine market
• – Sales value of China’s Capecitabine 2016-2020
• – Competitive landscape of China’s Capecitabine market
• – Prices of Capecitabine in China
• – Prices of Capecitabine in China by regions and manufacturers
• – Analysis on factors affecting the development of China’s Capecitabine market
• – Prospect of China’s Capecitabine market from 2021 to 2025

The post Investigation Report on China’s Capecitabine Market 2021-2025 first appeared on CRI Report.

According to CRI’s market research, the sales value of Linezolid in the Chinese market increased year by year from 2016 to 2019. In 2020, due to the impact of COVID-19 on the overall diagnosis and treatment services of the hospital, the sales value of Linezolid in the Chinese market fell to CNY695 million in 2020, a year-on-year decrease of 14.89%. However, the CAGR of Linezolid sales value in the Chinese market from 2016 to 2020 is still 14.45%.

CRI expects that with the relief of COVID-19, the sales value of Linezolid in the Chinese market will have a restorative growth from 2021 to 2025. In addition, Linezolid has high antibacterial activity against Staphylococcus, Streptococcus pneumoniae, and Enterococcus bacteria, and has no cross-resistance with other antibacterial drugs. It is currently the first choice for the treatment of severe infections such as septic shock. These advantages make sales value and sales volume have room to rise.

Topics Covered:

• -The impact of COVID-19 on China’s Linezolid market
• – Sales value of China’s Linezolid 2016-2020
• – Competitive landscape of China’s Linezolid market
• – Prices of Linezolid in China
• – Prices of Linezolid in China by regions and manufacturers
• – Analysis on factors affecting the development of China’s Linezolid market
• – Prospect of China’s Linezolid market from 2021 to 2025

The post Investigation Report on China’s Linezolid Market 2021-2025 first appeared on CRI Report.